Accueil   Diary - News   All news Long-term survival analysis shows a clear clinical benefit of inolimomab in SR-aGvHD

Long-term survival analysis shows a clear clinical benefit of inolimomab in SR-aGvHD

 

 

  • Follow-up of INO-107 Phase III study patients up to 8.5 yearsis the first long term analysis of a randomized study in acute steroid-resistant graft versus host disease (SR-aGvHD)

  • Investigators letter published in Blood Advances journal completes the result of the initial analysis of INO-107 study and demonstrates clinical benefit of inolimomab in SR-aGvHD

  • This analysis shows a clear superiority of inolimomab against anti-thymocyte globulin

 

Lyon, FRANCE, 23 January 2019, ELSALYS BIOTECH, a new player in immuno-oncology, presentsthe results from long-term follow-up of INO-107 Phase III study patients up to 8.5 years. These results have been published in a Letter to Blood signed by the investigators demonstrating clinical benefit of inolimomab (LEUKOTAC®) in acute steroid-resistant graft versus host disease (SR-aGvHD).

 

Read the press release